基于血液生物标志物、粪便免疫化学检测和年龄的结直肠癌人群筛查算法的开发
这项前瞻性多中心研究纳入丹麦国家结直肠癌筛查项目中1977例粪便免疫化学检测(FIT)阳性并接受结肠镜随访者,将8种血液生物标志物、定量FIT结果与年龄组合构建交叉验证逻辑回归算法,并与仅用FIT结果的模型比较;算法判别结直肠癌与非结直肠癌的曲线下面积为0.77,优于FIT模型的0.67(P < .001)。
要点
- 算法联合8种血液生物标志物、定量FIT和年龄,判别结直肠癌与非结直肠癌的AUC为0.77,FIT模型为0.67(P < .001)。
- 判别结直肠癌或高/中风险腺瘤与低风险腺瘤或清洁结直肠时,算法与FIT模型的AUC分别为0.68和0.64。
- 作者认为该算法可改善患者分配至结肠镜的流程,减少结肠镜负担而不影响癌和腺瘤检出率,或反之。
核心结论
- 作者认为该算法能改善患者分配至结肠镜的流程,减少结肠镜负担而不影响癌和腺瘤检出率,或反之。
研究设计与样本
- 前瞻性多中心研究,纳入丹麦国家结直肠癌筛查项目中1977例FIT阳性并接受随访结肠镜的个体。
- 检测8种血液生物标志物(癌胚抗原、铁蛋白、高敏C反应蛋白、人附睾蛋白4、Cyfra21-1、hepsin、白细胞介素8和骨保护素),并在Architect i2000、Architect c8000或Luminex xMAP机器上分析。
- 将FIT分析和血液生物标志物数据与临床数据(即年龄和结肠镜发现)结合,构建交叉验证逻辑回归模型(算法),并与仅使用FIT结果的模型(FIT模型)在不同FIT阳性截断值下进行基准比较。
主要发现
- 队列包括结直肠癌(n = 240)、腺瘤(n = 938)或无肿瘤性病变(n = 799)个体。
- 交叉验证算法联合8种生物标志物、定量FIT结果和年龄,判别结直肠癌与非结直肠癌个体的效能优于FIT模型(受试者工作特征曲线下面积分别为0.77和0.67;P < .001)。
- 判别结直肠癌或高/中风险腺瘤个体与低风险腺瘤或清洁结直肠个体时,算法和FIT模型的受试者工作特征曲线下面积分别为0.68和0.64。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Implementation of screening modalities has reduced the burden of colorectal cancer (CRC), but high false positive rates pose a major problem for colonoscopy capacity. We aimed to create a tailored screening algorithm that expands the fecal immunochemical test (FIT) with a blood specimen and current age to improve selection of individuals for diagnostic colonoscopy. METHODS: In this prospective multicenter study, 8 blood-based biomarkers (carcinoembryonic antigen, ferritin, high-sensitivity C-reactive protein, human epididymis protein 4, Cyfra21-1, hepsin, interleukin 8, and osteoprotegerin) were investigated in 1977 FIT-positive individuals from the Danish national CRC screening program undergoing follow-up colonoscopy. Specimens were analyzed on Architect i2000, Architect c8000 (both from Abbott, Chicago, Ill, USA), or Luminex xMAP machines (MilliporeSigma, St. Louis, Mo, USA). FIT analyses and blood-based biomarker data were combined with clinical data (ie, age and colonoscopy findings) in a cross-validated logistic regression model (algorithm) benchmarked against a model solely using the FIT result (FIT model) applying different cutoffs for FIT positivity. RESULTS: The cohort included individuals with CRC (n = 240), adenomas (n = 938), or no neoplastic lesions (n = 799). The cross-validated algorithm combining the 8 biomarkers, quantitative FIT result, and age performed superior to the FIT model in discriminating CRC versus non-CRC individuals (area under the receiver operating characteristic curve, 0.77 vs 0.67, respectively; P < .001). When discriminating individuals with either CRC or high- or medium-risk adenomas versus low-risk adenomas or clean colorectum, the areas under the receiver operating characteristic curve were 0.68 versus 0.64 for the algorithm and FIT model, respectively. CONCLUSIONS: The algorithm presented here can improve patient allocation to colonoscopy, reducing colonoscopy burden without compromising cancer and adenoma detection rates or vice versa.
引用
- Petersen MM, Kleif J, Liggett J, et al. Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening. Gastrointest Endosc. 2024. PMID: 38908453. doi:10.1016/j.gie.2024.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。